XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

Company Overview

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Key Stats

• Today's Range: $1.13 to $1.13
• 50-Day Range: $3.43 to $5.20
• 52-Week Range: $0.92 to $3.15
• Volume: N/A
• Average Volume: 19,706 shs
• Market Capitalization: $6.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XTLB Stock Analysis - Frequently Asked Questions

How were XTL Biopharmaceuticals' earnings last quarter?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) released its earnings results on Monday, December, 30th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter.

When did XTL Biopharmaceuticals' stock split?

Shares of XTL Biopharmaceuticals reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of XTL Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP).

Company Calendar

• Last Earnings: 12/30/2024
• Today: 4/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XTLB
• CIK: 1023549
• Web: www.xtlbio.com
• Phone: (729) 955-7080
• Fax: 972-3611-6605
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: 2.76

Miscellaneous

• Outstanding Shares: 5,450,000
• Free Float: 3,869,000
• Market Cap: $6.16 million
• Optionable: Not Optionable
• Beta: 1.13